Please try another search
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Name | Age | Since | Title |
---|---|---|---|
Laura A. Brege | 66 | 2019 | Independent Director |
Rodney G. Hill | 56 | 2018 | Independent Director |
John Lee Welborn | 47 | 2021 | Independent Chairman of the Board |
Kyle Dempsey | 34 | 2022 | Independent Director |
Craig Stuart Millian | 56 | 2023 | CEO & Director |
John Hanna | - | 2023 | Interim CFO & Non-Independent Director |
Christian Roy | 60 | 2023 | Independent Director |
Norma Beauchamp | 62 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review